Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Show: All - Companies - Funds
Results 1 - 40 of about 4293 companies and 273 funds for PH
Company Exchange Symbol Last price Quote change Market cap
Apple Inc. NASDAQ AAPL 152.09 +1.82 (1.21%) 792.60B
Apple Inc. (Apple) designs, manufactures and markets mobile communication and media devices, personal computers, and portable digital music players, and a ...
Executive:
Art D. Levinson Ph.D.
Parker-Hannifin Corp NYSE PH 164.40 -0.14 (-0.09%) 21.71B
Parker-Hannifin Corporation is a manufacturer of motion and control technologies and systems, providing precision engineered solutions for a range of mobile, ...
Biogen Inc NASDAQ BIIB 284.70 +1.78 (0.63%) 60.71B
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with ...
Executive:
Alexander J. Denner Ph.D.
P H Glatfelter Co NYSE GLT 20.01 -0.06 (-0.30%) 860.46M
PH Glatfelter Company is a manufacturer of specialty papers and fiber-based engineered materials. The Company operates through three business units: ...
Exelixis, Inc. NASDAQ EXEL 28.11 +0.88 (3.23%) 8.30B
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care ...
Executive:
Alan M. Garber MD Ph.D.
Gilead Sciences, Inc. NASDAQ GILD 74.39 +0.63 (0.85%) 97.66B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need.
Executive:
John C. Martin Ph.D.
Alphabet Inc NASDAQ GOOGL 998.31 +4.47 (0.45%) 684.42B
Alphabet Inc. is a holding company. The Company's businesses include Google Inc. (Google) and its Internet products, such as Access, Calico, CapitalG, GV, ...
Executive:
Eric E. Schmidt Ph.D.
Celldex Therapeutics, Inc. NASDAQ CLDX 2.39 +0.03 (1.27%) 296.49M
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy ...
Executive:
Gerald McMahon Ph.D.
Intuitive Surgical, Inc. NASDAQ ISRG 949.17 +21.70 (2.34%) 33.38B
Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da ...
Executive:
Alan J. Levy Ph.D.
CTI BioPharma Corp NASDAQ CTIC 3.43 +0.02 (0.59%) 94.06M
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a ...
Executive:
Adam R. Craig MD, Ph.D.
Regeneron Pharmaceuticals Inc NASDAQ REGN 521.22 +5.30 (1.03%) 54.85B
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers , invents, develops, manufactures and commercializes medicines for the ...
Executive:
Bonnie Bassler Ph.D.
Neurocrine Biosciences, Inc. NASDAQ NBIX 48.69 +1.62 (3.44%) 4.22B
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and ...
Executive:
Dimitri E. Grigoriadis Ph.D.
Capricor Therapeutics Inc NASDAQ CAPR 1.12 -0.19 (-14.50%) 26.10M
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics.
Executive:
Houman Hemmati MD, Ph.D.
Vertex Pharmaceuticals Incorporated NASDAQ VRTX 166.11 +2.94 (1.80%) 42.37B
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company ...
Executive:
Alan Garber MD Ph.D.
Geron Corporation NASDAQ GERN 2.88 +0.08 (2.86%) 456.80M
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic ...
Executive:
Andrew J. Grethlein Ph.D.
Albireo Pharma Inc NASDAQ BIOD 19.46 225.48M
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid ...
Executive:
David Chiswell Ph.D.
Johnson & Johnson NYSE JNJ 133.01 -2.30 (-1.70%) 355.00B
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare ...
Executive:
Mark B. McClellan MD, Ph.D.
Ionis Pharmaceuticals Inc NASDAQ IONS 59.56 +3.17 (5.62%) 7.45B
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery ...
Executive:
Brett P. Monia Ph.D.
Chevron Corporation NYSE CVX 103.20 -0.06 (-0.06%) 192.94B
Chevron Corporation (Chevron) manages its investments in subsidiaries and affiliates, and provides administrative, financial, management and technology ...
Executive:
Alice P. Gast Ph.D.
Amarin Corporation plc (ADR) NASDAQ AMRN 4.12 -0.04 (-0.96%) 1.11B
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for ...
Executive:
Craig B. Granowitz MD, Ph.D.
Show all 4293 companies »
Mutual Fund Symbol Nav Nav change
Trimark Global Balanced Class Series PH AIM45511 15.20 -0.02 (-0.12%)
This Fund strives for long-term capital growth and current income by investing in a mix of equities and fixed-income securities. The equity portion is mainly ...
Trimark Global Fundamental Equity Cl PH AIM40681 18.89 -0.04 (-0.20%)
The Fund's investment objective is to achieve strong capital growth with a high degree of reliability over the long term. The Fund invests primarily in equities of ...
Trimark US Companies Class Series PH AIM40691 20.72 +0.02 (0.10%)
The Fund's investment objective is to provide strong capital growth over the long term. The Fund invests primarily in equities of American companies. AIM is not ...
CIFM (HK) RMB Diversified Income Fund Class PH CIFM_HK_RMB_1GUSU9R 90.62 -0.05 (-0.06%)
CIFM (HK) RMB Diversified Income Fund seeks to achieve long term capital appreciation by investing in debt securities and equity securities which are ...
Trimark Global Endeavour Class Series PH AIM41761 11.17 -0.05 (-0.45%)
The Fund seeks to generate long-term capital growth by investing primarily in mid -cap equity securities from anywhere in the world.
Invesco International Growth Class Series PH AIM42761 11.24 -0.03 (-0.28%)
The fund seeks to provide long-term capital growth by primarily investing in a diversified portfolio of international equity securities. The Fund emphasizes mid- ...
PH & N Canadian Equity Pension Trust SrO RBF8240 8.12 -0.01 (-0.13%)
The fundamental investment objective of the fund is to provide significant long- term capital growth by investing primarily in a well-diversified portfolio of ...
Trimark Global Dividend Class Series PH AIM40761 11.10 -0.02 (-0.19%)
This Fund seeks to generate a total return over the long term by investing primarily in dividend-paying equity securities of companies located anywhere in the ...
Fidelity´┐Ż Select Pharmaceuticals Portfolio FPHAX 19.35 -0.05 (-0.26%)
The investment seeks capital appreciation. The fund normally invests at least 80 % of assets in companies engaged in the research, development, manufacture, ...
Virtus Duff & Phelps Real Estate Securities Fund Class A PHRAX 30.35 -0.01 (-0.03%)
The investment seeks capital appreciation and income with approximately equal emphasis. The fund normally invests at least 80% of its assets in publicly-traded ...
Glenmede Philadelphia International Fund GTIIX 13.11 +0.04 (0.31%)
The investment seeks maximum long-term total return consistent with reasonable risk to principal. The fund invests primarily in common stocks, including ...
PH&N Monthly Income Series C RBF7660 9.50 -0.02 (-0.25%)
The fundamental investment objective of the Fund is to provide a relatively high monthly income that may consist of dividend income, interest income, realized ...
PH&N Dividend Income D RBF1150 102.49 -0.30 (-0.29%)
To provide long-term capital growth and income by investing primarily in a well- diversified portfolio of dividend income-producing Canadian securities that have ...
ProFunds Pharmaceuticals UltraSector Fund Investor Class PHPIX 25.70 -0.25 (-0.96%)
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow ...
RBC PH&N Monthly Income RBF501 10.75 -0.11 (-0.97%)
To provide a relatively high monthly income that may consist of dividend income, interest income, realized capital gains and a return of capital, with the potential ...
Virtus Duff & Phelps Real Estate Securities Fund Class I PHRIX 30.31 -0.01 (-0.03%)
The investment seeks capital appreciation and income with approximately equal emphasis. The fund normally invests at least 80% of its assets in publicly-traded ...
PH&N Bond D RBF1110 10.22 -0.02 (-0.19%)
To provide relatively high yields and stability of capital by investing primarily in a well-diversified portfolio of fixed income securities issued by Canadian ...
Virtus Duff & Phelps Global Infrastructure Fund Class A PGUAX 14.99 -0.07 (-0.46%)
The investment seeks capital appreciation and current income. The fund invests globally in infrastructure companies involved in the energy, utility, transportation, ...
Phillips, Hager & North Inflation-Linked Bond Fund Series D RBF1650 10.59 +0.02 (0.15%)
The fundamental investment objective of the Fund is to generate interest income that is hedged against inflation by investing primarily in real return bonds and ...
Virtus Duff & Phelps Global Real Estate Securities Fund Class A VGSAX 28.33 -0.02 (-0.07%)
The investment seeks long-term capital appreciation with a secondary investment objective of income. The fund provides global exposure to the real estate ...
Show all 273 funds »